Navigation Links
IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
Date:8/28/2012

MOUNTAIN VIEW, Calif., Aug. 28, 2012 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that its board of Directors has named medical device industry veteran William M. Moore., age 63, as interim President and Chief Executive Officer, effective immediately.  Moore replaces Dominik Beck, whose employment with the Company ceased on August 24, 2012.  Moore currently serves, and will continue to serve, as Chairman of the IRIDEX Board of Directors during his tenure as interim Chief Executive Officer.  He has served as a director of the Company since September 2007.

The Company also announced that the Board has appointed James Mackaness, age 48, as Chief Operating Officer, effective immediately. Mr. Mackaness will continue to serve in his role as the Company's Chief Financial Officer.  Mackaness joined the Company in January 2008 as Chief Financial Officer. Mackaness stated, "I am very glad to have this opportunity to work more closely with Mr. Moore and the board of directors as the company's Chief Operating Officer.  IRIDEX is a global leader in ophthalmology and I believe well positioned to deliver on its long-standing commitment to profitable operations as we continue to evolve and expand the business."

In assuming the President and CEO role, Moore indicated that he will lead the company's strategic direction and execution in order to increase shareholder value while Mackaness will assume more of the day-to-day operational responsibilities at IRIDEX.

Moore stated, "IRIDEX is in the unique and positive position of having both established and emerging products targeted at large and growing markets. The company has many assets, including technologies and intellectual property associated with a potential paradigm-changing means of treating serious eye conditions, a stable balance sheet and a talented team of employees.  Having been a board member for more than 5 years, I am excited about this opportunity to serve as the President and CEO of IRIDEX.  I am committed to representing the interests of all stakeholders as we work to build shareholder value."

Moore co-founded Natus Medical Incorporated, a public company, in 1990 where he served as CEO until 1993. Natus Medical is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and certain newborn conditions.  Mr. Moore still serves on the Natus Board of Directors.  Moore also served as a consultant to BlueLine Partners, a private equity firm and investor in IRIDEX, from February 2004 until June 2008. He also served on the Board of Directors of Urologix, Inc., a public medical device company. Moore holds a B.S. in Business from the University of Utah.

Mackaness served as Chief Financial Officer and Vice President of Finance of NextHop Technologies, Inc., a networking wireless technology company from September 2001 to December 2007.  Prior to that, he served as Vice President, Finance and Chief Financial Officer of Infogear Technologies Corporation and held management positions at Cisco Systems, Inc. and Ernst & Young LLP. Mackaness received his B.A. with honors in Psychology from the University of Warwick, England and is a Chartered Accountant and member of the Institute of Chartered Accountants of England and Wales.

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology and otolaryngology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the Company's website at http://www.iridex.com/.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the Company's strategy and its ability to execute on that strategy and the ability to increase shareholder value.  These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors.  Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2012 and June 30, 2012, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
2. IRIDEX Reports 2012 First Quarter Results
3. IRIDEX Announces Second Quarter 2012 Conference Call and Release Date
4. IRIDEX Reports 2012 Second Quarter Results
5. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
6. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
7. Nephros Appoints John C. Houghton as President and Chief Executive Officer
8. Elsevier Appoints New President of Elsevier CPM Resource Center
9. GenWay Biotech Appoints New Vice President of Custom/OEM
10. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
11. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 2017 AVACEN Medical , Inc. (AVACEN) announced ... 2017 New Product Innovation Award for Its fibromyalgia pain ... secondary medical device market research by Frost & Sullivan,s industry ... drug-free pain relief product, the AVACEN 100, offers a safe ... widespread pain. ...
(Date:10/12/2017)... Oct. 12, 2017 West Pharmaceutical Services, ... solutions for injectable drug administration, today announced that it ... opens on Thursday, October 26, 2017, and will follow ... business expectations at 9:00 a.m. Eastern Time. To participate ... (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, ... relay – Miles by Moonlight to raise money for the American Heart Association Heart ... , Teams will work together to keep their treadmills moving for 5 hours. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in wound care advancements to physician colleagues, skilled nursing facility medical directors and ... the Treacherous Waters of Wound Care." , "At many of these conferences we ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... its enhanced Pepper Flow promotional review platform at the Promotional Review Committee ... insight-driven capabilities help marketers streamline the medical, legal, and regulatory review (MLR) ...
Breaking Medicine News(10 mins):